Entities / Company
Medpace.
medical Services Corporation
- Reports this week
- 3
- Active events
- 1
- Connections
- 77
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
TD Cowen and Mizuho Securities have both lifted their price targets for Medpace shares.Some support1 report
-
Medpace traded on the NASDAQ stock exchange on August 26, 2026.Some support2 reports
-
Medpace filed required documents with the Securities and Exchange Commission on August 15, 2026.Some support1 report
-
An investigation has been announced in New York City involving the company Medpace.Some support1 report
-
Avantor and Medpace operate in the life sciences tools & services segment.Some support1 report
-
Renaissance Technologies increased its stake in Medpace, which subsequently filed disclosures with the SEC.Some support1 report
-
David Taylor made various stock market transactions on June 25, 2026, including buying and selling shares of multiple companies.Some support2 reports
Gone quiet
No new reports in 90+ days-
Medpace was listed on the electronic stock exchange on June 15, 2026.Some support1 report
-
Medpace stock is listed on Nasdaq and is held as a core position by the Madison Small Cap Fund.Some support4 reports
-
Fund holdings pulled back due to AI disruption fears.Some support1 report
-
IQVIA and Medpace reported strong earnings amid industry rebound, while China remains a key source of raw ingredients.Some support2 reports
-
Dover manufactures equipment for the US military, while Medpace provides services to US biotech companies.Speculative1 report
-
Medpace is headquartered in Cincinnati, Ohio, and Lauren Morris serves as the Investor Contact for the company.Speculative1 report
-
Barclays initiated coverage and set a price target for Medpace.Speculative1 report
-
Both Medpace and UFP Technologies operate in the drug development inputs and services segment.Speculative1 report
-
Medpace reported that its earnings growth lags its share price CAGR.Some support1 report1 development inside
-
High ROE and profit retention drive earnings growth for Medpace.Speculative1 report
-
Truist trimmed its price target for Medpace on July 9, 2025.Speculative1 report
-
Medpace and Microsoft are mentioned in the context of future enterprise software stocks.Some support9 reports
-
Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.Some support2 reports
-
UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date.Some support2 reports1 development inside
-
Medpace CEO provided commentary on the company's Q2 performance on July 28, 2025.Some support1 report
-
Calix, Medpace, and West Pharmaceutical Services reported significant stock gains on July 28, 2025, comparing their performance to the S&P 500.Some support1 report
-
Golden Cross signals potential bullish breakout involving Brink's on August 13, 2025.Some support2 reports
-
West Pharmaceutical Services, Azenta, and Medpace are noted as companies operating in the drug development inputs and services segment.Some support1 report
-
Cencora and Medpace were analyzed for value investment on August 28, 2025, with Cencora receiving a superior Value grade (A) over Medpace (D).Some support1 report
-
Medpace common stock traded on NASDAQ while a lawsuit was filed in S.D. Ohio.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Medpace this week
News at the entities that move Medpace most-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Medpace
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Medpace
-
TD Cowen OperationalAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Medpace
-
UBS OperationalThe Swiss parliament has proposed stricter capital requirements for UBS.Moves Medpace
-
Royal Bank of Canada OperationalRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Medpace
-
Renaissance Technologies StructuralRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Medpace
Connections
The 17 strongest of 77, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Medpace operates under the mandatory oversight and disclosure rules of the SEC.
-
Securities and Exchange Commission Structural
Medpace is subject to formal regulation and filing requirements imposed by the Securities and Exchange Commission.
-
Nasdaq Shared context
Medpace's common stock is listed and traded on the Nasdaq stock exchange.
-
TD Cowen Operational
TD Cowen provides professional financial analysis, including ratings and price targets, for Medpace.
-
Mizuho Securities Operational
Mizuho Securities provides market analysis and price targets for Medpace shares.
-
Renaissance Technologies Structural
Renaissance Technologies is increasing its investment position in Medpace.
-
UBS Operational
UBS downgraded Medpace stock to 'Sell' following an assessment of client risk.
-
Avantor Shared context
Both companies operate within the life sciences tools and services segment.
Show all 17 connections
-
Truist Financial Mentioned together
Truist Financial provides investment analysis, raising price targets for Medpace.
-
David Taylor Transactional
David Taylor purchased shares of Medpace.
-
Barclays Mentioned together
Barclays provides sell-side research, including price targets and coverage, on Medpace.
-
Cencora Operational
Both companies are analyzed and compared as competitors in the value investment market.
-
IQVIA Mentioned together
IQVIA and Medpace are noted as peers operating within the life sciences tools segment.
-
Royal Bank of Canada Operational
Royal Bank of Canada has issued a positive target price assessment for Medpace.
-
California Shared context
Medpace operates within the healthcare market context of California, where they are compared against peers.
-
Ohio Shared context
Medpace is currently involved in legal proceedings within the jurisdiction of Ohio.
-
New York City Shared context
Medpace is subject to an investigation announced in New York City.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
4 events- TD Cowen and Mizuho Securities have both lifted their price targets for Medpace shares.
- Medpace traded on the NASDAQ stock exchange on August 26, 2026.
- Medpace filed required documents with the Securities and Exchange Commission on August 15, 2026.
- An investigation has been announced in New York City involving the company Medpace.
July 2026
2 eventsShow 1 earlier month
June 2026
21 events- David Taylor made various stock market transactions on June 25, 2026, including buying and selling shares of multiple companies.
- Medpace was listed on the electronic stock exchange on June 15, 2026.
- Medpace stock is listed on Nasdaq and is held as a core position by the Madison Small Cap Fund.
- Fund holdings pulled back due to AI disruption fears.
- IQVIA and Medpace reported strong earnings amid industry rebound, while China remains a key source of raw ingredients.
- Dover manufactures equipment for the US military, while Medpace provides services to US biotech companies.
- Medpace is headquartered in Cincinnati, Ohio, and Lauren Morris serves as the Investor Contact for the company.
- Barclays initiated coverage and set a price target for Medpace.
- Both Medpace and UFP Technologies operate in the drug development inputs and services segment.
- Medpace reported that its earnings growth lags its share price CAGR.
- High ROE and profit retention drive earnings growth for Medpace.
- Truist trimmed its price target for Medpace on July 9, 2025.
- Medpace and Microsoft are mentioned in the context of future enterprise software stocks.
- Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.
- UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date.
- Medpace CEO provided commentary on the company's Q2 performance on July 28, 2025.
- Calix, Medpace, and West Pharmaceutical Services reported significant stock gains on July 28, 2025, comparing their performance to the S&P 500.
- Golden Cross signals potential bullish breakout involving Brink's on August 13, 2025.
- West Pharmaceutical Services, Azenta, and Medpace are noted as companies operating in the drug development inputs and services segment.
- Cencora and Medpace were analyzed for value investment on August 28, 2025, with Cencora receiving a superior Value grade (A) over Medpace (D).
- Medpace common stock traded on NASDAQ while a lawsuit was filed in S.D. Ohio.